Drug checking results
Current warnings and particularities
Current warnings February 2018
Since the beginning of February 2018, we have tested a number of substances of particular health concern. In a sample submitted for analysis as an ecstasy tablet, the new psychoactive substance 2C-P (2,5-dimethoxy-4-propylphenethylamine) identified. Instead of the expected active ingredient, a supposed MDMA sample showed the new psychoactive substance Clephedrone (4-CMC) from the cathinone group.
Current warnings February 2018
Current warnings January 2018
Since the beginning of January 2018, we have tested a number of substances of particular health concern. In addition to a large number of amphetamine samples laced with caffeine, many samples submitted as alleged ecstasy contained high to very high levels of the active ingredient MDMA. In one sample submitted as an unknown substance, the new psychoactive substances 4-chloro-alpha-PVP (4Cl-PVP, 4-chloro-alpha-pyrrolidinovalerophenone) and N-ethylhexedrone (NEH) was identified. An alleged cocaine sample contained cocaine, amphetamine, caffeine and the two new psychoactive substances N-ethylhexedrone (NEH) and MPHP (4'-methyl-α-pyrrolidinohexiophenone).
Current warnings December 2017
Since the beginning of December 2017, we have tested a number of substances of particular health concern. In addition to a series of ecstasy tablets with a (very) high MDMA content, an unknown substance was identified in two tablets alongside the expected active ingredient MDMA. The hallucinogenic substance 2C-B was detected in a further two supposed ecstasy tablets. The new psychoactive substance Clephedrone (4-CMC) was identified in one sample submitted as MDMA, one as mephedrone and one as cocaine. In addition to clephedrone (4-CMC), the following cathinone derivatives were found in various samples: Methylone (bk-MDMA), Dimethylone (bk-MDDMA), 4-Chloroethcathinone (4-CEC), Methyl ethyl cathinone (4-MEC).
Current warnings November 2017
Since the beginning of November 2017, we have tested a number of substances of particular health concern. In addition to the expected active ingredient MDMA, one tablet sold as ecstasy contained a unknown substance identified. In addition to MDMA, another ecstasy tablet contained the new psychoactive substance Methylone (3,4-methylenedioxymethcathinone, bk-MDMA) on. In addition to the expected amphetamine, a sample given as speed also contained caffeine and the hallucinogenic substance 2C-E (2,5-dimethoxy-4-ethylphenethylamine).
Current warnings October 2017
Since the beginning of October 2017, we have tested a number of substances that pose a particular health risk. In addition to Ethylphenidate and four new psychoactive substances from the cathinone group (4-CMC, 4-CEC, 3-MMC, N-ethylbuphedrone), a total of four new psychoactive substances from the opioid group were identified in various samples. In one of the 4-Hydroxymethylethyltryptamine (4-HO-MET) was analysed in addition to this expected tryptamine. Methoxyacetylfentanyla previously unexplored fentanyl analogue, was detected. In a sample delivered as fentanyl, the highly potent Opioid Carfentanyl was detected. Four further samples were submitted as unknown research chemicals: three of them contained the opioid U-47700 one contained the opioid Cyclopentylfentanyl. U-47700 and cyclopentylfentanyl are substances that have hardly been researched to date.
Current warnings July 2017 / Part 2
Since the beginning of July 2017, we have tested a number of substances of particular health concern. In addition to some ecstasy tablets, some of which contained very high doses, one sample submitted for analysis as MDMA contained the new psychoactive substance 4-Chloroethcathinone (4-CEC) was detected. In a sample submitted for analysis as LSD, the new psychoactive substance 1-acetyl-LSD (ALD-52) was identified.
Current warnings July 2017 / Part 2
Current warnings July 2017
Since the beginning of July 2017, we have tested a number of substances of particular health concern. Many ecstasy tablets, some of which contained very high doses (up to 331 mg MDMA), were handed in for analysis. The anthelmintic levamisole was identified in many of the samples submitted for analysis as cocaine. The majority of the samples submitted for analysis as speed also contained caffeine in varying proportions. In MDMA samples, the new psychoactive substances
N-Ethylpentylone, Clephedrone (4-CMC) resp. 4-Chloroethcathinone (4-CEC) proven.
Current warnings June 2017
Since the beginningng June 2017, we tested a number of substances of particular health concern. In addition to some ecstasy tablets with a (very) high MDMA content, one of the tablets handed in also contained caffeine in addition to MDMA. In addition to cocaine, the anthelmintic levamisole was detected in the majority of the samples submitted for analysis as cocaine. The new psychoactive substances 3-Methylmethcathinone (3-MMC) and Clephedrone (4-CMC) resp. 4-Chloroethcathinone (4-CEC) were found in a sample submitted as mephedrone and as ketamine. In a sample submitted as "unknown", the new psychoactive substance N-Ethylpentylone (bk-EBDP, Ephylone) identified.
The following link lists all samples that have been submitted to us in the period from 1 June 2017 to date. checkit! analysed and classified as high-dose, unexpected or of particular health concern.